<DOC>
	<DOC>NCT00126425</DOC>
	<brief_summary>The study is designed to study the utility of 123I-mIBG as a diagnostic imaging agent to predict cardiac outcomes in subjects with heart failure and in comparison to subjects without cardiovascular disease.</brief_summary>
	<brief_title>Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>3-Iodobenzylguanidine</mesh_term>
	<criteria>Study subjects must be adults with an established diagnosis of heart failure (New York Heart Association Class II or III) and reduced left ventricular ejection fraction (LVEF) (â‰¤ 35%) or be healthy volunteers without heart disease. Healthy volunteers are not eligible if they have a history diabetes mellitus, signs/symptoms of neurological disease (eg, Parkinson's Disease, multiple system atrophy, Parkinsonian syndromes), or other diseases known to affect the sympathetic nervous system. Subjects with New York Heart Association Class I or IV heart failure are not eligible.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>nuclear cardiology</keyword>
	<keyword>sympathetic innervation</keyword>
	<keyword>123I-mIBG</keyword>
</DOC>